MST Continus suspension 200mg granules sachets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Morphine sulfate

Available from:

Napp Pharmaceuticals Ltd

ATC code:

N02AA01

INN (International Name):

Morphine sulfate

Dosage:

200mg

Pharmaceutical form:

Modified-release granules

Administration route:

Oral

Class:

Schedule 2 (CD)

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 04070200; GTIN: 5012854039186

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER
_MST_
_®_
_ CONTINUS_
_®_ 20 MG, 30 MG, 60 MG, 100 MG AND 200 MG PROLONGED-RELEASE SUSPENSIONS
Morphine sulfate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What _MST CONTINUS _suspension is and what it is used for
2.
What you need to know before you take _MST CONTINUS _suspension
3.
How to take _MST CONTINUS _suspension
4.
Possible side effects
5.
How to store _MST CONTINUS _suspension
6.
Contents of the pack and other information
1.
WHAT _MST CONTINUS _SUSPENSION IS AND WHAT IT IS USED FOR
This suspension has been prescribed for you by your doctor to relieve
severe pain over a period of 12 hours. It
contains the active ingredient morphine which belongs to a group of
medicines called strong analgesics or
‘painkillers’.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE _MST CONTINUS_ SUSPENSION
DO NOT TAKE _MST CONTINUS _SUSPENSION IF:

you are allergic (hypersensitive) to morphine or any of the other
ingredients of the suspension (listed
in section 6);

you have breathing problems, such as obstructive airways disease or
respiratory depression. Your
doctor will have told you if you have these conditions. Symptoms may
include breathlessness,
coughing or breathing more slowly or weakly than expected;

you have a head injury that causes a severe headache or makes you feel
sick. This is because the
suspensions may make these symptoms worse or hide the extent of the
head injury;

you have a condition where the small bowel (part of your gut) do

Summary of Product characteristics

OBJECT 1
MST CONTINUS SUSPENSION 20 MG
Summary of Product Characteristics Updated 20-Mar-2018 | Napp
Pharmaceuticals Limited
1. Name of the medicinal product
MST
®
CONTINUS
®
suspension 20, 30, 60, 100 and 200 mg.
2. Qualitative and quantitative composition
Each sachet contains Morphine equivalent to Morphine Sulfate 20, 30,
60, 100 and 200 mg.
Excipients with known effect:
Ponceau 4R (E124)
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Prolonged release granules for oral suspension.
Pink granules.
4. Clinical particulars
4.1 Therapeutic indications
For the prolonged relief of severe and intractable pain.
4.2 Posology and method of administration
Posology
Adults:
A patient presenting with severe pain, uncontrolled by weaker opioids
(e.g. dihydrocodeine) should
normally be started on 30 mg 12-hourly. Patients previously on normal
release oral morphine should be
given the same total daily dose as MST CONTINUS suspension but in
divided doses at 12-hourly
intervals.
Increasing severity of pain will require an increased dosage of the
suspension. Higher doses should be
made, where possible in 30-50% increments as required. The correct
dosage for any individual patient is
that which is sufficient to control pain with no, or tolerable, side
effects for a full 12 hours. It is
recommended that the 200 mg strength is reserved for patients who have
already been titrated to a stable
analgesic dose using lower strengths of morphine or other opioid
preparations.
Patients receiving MST CONTINUS suspension in place of parenteral
morphine should be given a
sufficiently increased dosage to compensate for any reduction in
analgesic effects associated with oral
administration. Usually such increased requirement is of the order of
100%. In such patients individual
dose adjustments are required.
Paediatric Population:
The use of MST CONTINUS suspension in children has not been
extensively evaluated. For children
with severe cancer pain, a starting dose in the range of 0.2 to 0.8 mg
morphine per kg bodyweigh